Digital Standardization: Accelerating Gene Therapy Tech Transfer With Confidence And Compliance

By Ane Quesada, senior scientist – MSAT, Viralgen and Joschka Buyel, principal product scientist, QbDVision

Fragmented, document-driven data practices continue to hinder biopharmaceutical tech transfer, introducing inefficiencies, repeated review cycles, and heightened compliance risk. Disconnected systems, inconsistent templates, and reliance on manual data handling create significant barriers to aligning cross-functional teams and maintaining version control, ultimately slowing onboarding and delaying progress toward commercialization.

A shift to centralized, structured digital CMC frameworks addresses these challenges by unifying process knowledge, product-specific data, and risk assessments within a single, validated system. This approach enables real-time collaboration, ensures consistency across all outputs, and reduces the likelihood of errors caused by redundant data entry or misaligned documentation. Automated capabilities, such as scaling, change propagation, and gap analysis, further streamline workflows and support more predictable, efficient transfers.

By consolidating platform knowledge into a continuously evolving data backbone, organizations can reuse prior learnings, accelerate process fit, and improve overall development agility while maintaining compliance. A representative case study demonstrates how adopting such a model can significantly compress onboarding timelines while preserving quality-by-design rigor. Collectively, these advances signal a broader transformation toward data-centric development, where speed, transparency, and reliability are foundational to successful tech transfer.